Journal of Shanghai University >
Effects of Chinese patent medicines on left ventricular ejection fraction and brain natriuretic peptide in patients with chronic heart failure: systematic review#br# and Meta-analysis
Received date: 2016-04-20
Online published: 2016-06-30
To evaluate efficacy and security of Chinese patent medicines on left ventricular ejection fraction (LVEF) and plasma brain natriuretic peptide (BNP) in the treatment of heart failure (HF). Five databases including PubMed, The Cochrane Library, CNKI, VIP and WanFang Data have been searched to identify relevant randomized controlled trials (RCTs) up till March 2016. Methodological quality of the included studies was assessed using criteria from Cochrane Reviewer’s Handbook 5.3, and analyzed using Rev Man 5.3 software. Sixteen RCTs of Chinese patent medicines were included. Results of the Meta-analysis showed that Chinese patent medicines were more effective on LVEF (MD=5.80, 95%CI (confidence interval): 0.236.73, P < 0.01) and BNP (MD= −366.99, 95%CI: −412.00 −321.97, P < 0.01). In addition, assessed quality of the included randomized controlled trials were low. Based on low quality and limited data, Chinese patent medicines were more significant at the LVEF and BNP level. Therefore, sufficient high quality experiments need to be conducted to confirm efficacy and security of Chinese patent medicines.
LIU Shuo1, LI Min1, CHEN Shiqi1, QIU Ruijin1, ZHANG Qin1, ZHAO Mingjing1, CHEN Jing2, SHANG Hongcai1 . Effects of Chinese patent medicines on left ventricular ejection fraction and brain natriuretic peptide in patients with chronic heart failure: systematic review#br# and Meta-analysis[J]. Journal of Shanghai University, 2016 , 22(3) : 357 -365 . DOI: 10.3969/j.issn.1007-2861.2016.03.017
[1] Warnes C, Williams R G, Bashore T M, et al. ACC/AHA 2008 guidelines for the management of adults with congenital heart disease [J]. Journal of the American College of Cardiology, 2008, 52(23): 1890-1947.
[2] 杨跃进, 华伟. 阜外心血管内科手册[M]. 北京: 人民卫生出版社, 2012.
[3] 沈会, 李柳骥. 心力衰竭[M]. 北京: 人民军医出版社, 2008.
[4] 武双平, 常丽萍, 袁国强, 等. 芪苈强心胶囊改善慢性收缩性心力衰竭患者血管内皮功能的临床观察[J]. 疑难病杂志, 2014(8): 827-830.
[5] Li X L, Zhang J, Huang J, et al. A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of Qili Qiangxin capsules in patients with chronic heart
failure [J]. Journal of the American College of Cardiology, 2013, 62(12): 1065-1072.
[6] 田野, 李彦霞, 任君霞, 等. 芪苈强心胶囊治疗舒张性心衰的疗效观察[J]. 中国临床药理学杂志, 2011, 27(9): 666-668.
[7] 魏小英, 张俭. 中药治疗冠心病合并慢性心力衰竭的疗效观察[J]. 医药前沿, 2014(18): 347-348.
[8] 李彦霞, 袁国强, 贾振华. 芪苈强心胶囊对舒张性心衰患者生活质量及血浆NT-proBNP 水平的影响[J]. 中国中医基础医学杂志, 2012(3): 289-291.
[9] 王秀珍. 芪苈强心胶囊治疗慢性心力衰竭的疗效观察[J]. 光明中医, 2012, 27(5): 1566-1567.
[10] 李静. 观察芪苈强心胶囊治疗舒张性心力衰竭的临床疗效[J]. 中国医药指南, 2013(9): 286-287.
[11] 张颖莉, 朱雪梅. 益心舒胶囊治疗舒张性心力衰竭的临床观察[J]. 中西医结合心脑血管病杂志, 2011, 9(3): 287-289.
[12] 陈伟, 吴哲乾, 凌云. 益心舒胶囊早期应用对充血性心力衰竭患者心功能及细胞因子的影响[J]. 中西医结合心脑血管病杂志, 2009, 7(4): 387-388.
[13] 刘英圣, 修明文, 付金香, 等. 参松养心胶囊对慢性心力衰竭患者再住院率的影响[J]. 中国误诊学杂志, 2011, 11(22): 5330-5331.
[14] 杨义航, 徐道英, 向立权. 参松养心胶囊治疗慢性收缩性心力衰竭122 例[J]. 中国药业, 2010, 19(18): 74-75.
[15] 邵玲. 脑心通治疗慢性心力衰竭的临床疗效及对生活质量的影响[J]. 中国老年学杂志, 2015, 35(7): 1781-1782.
[16] 王亚宽, 丁志欣, 白晓艳. 强心宁衰口服液治疗慢性充血性心力衰竭的临床研究[J]. 中国中医急症, 2014, 23(4): 682-683.
[17] 蒙莫珂. 芪参益气滴丸治疗老年慢性心力衰竭疗效观察[J]. 中国误诊学杂志, 2010, 10(13): 3097-3098.
[18] 韩轶, 陈继红, 李鹏, 等. 心悦胶囊治疗冠心病慢性充血性心衰气虚血瘀型54 例临床疗效观察[J]. 重庆医科大学学报, 2011, 36(3): 372-374.
[19] 王永刚, 钟伟, 于远望, 等. 参附芎泽胶囊治疗慢性心力衰竭59 例临床观察[J]. 中医杂志, 2013, 54(3): 218-221.
[20] Hou Y Z, Wang S, Zhao Z Q, et al. Clinical assessment of complementary treatment with Qishen Yiqi dripping pills on ischemic heart failure: study protocol for a randomized, doubleblind, multicenter, placebo-controlled trial (CACT-IHF) [J]. Trials, 2013, 14(1): 1-7.
[21] Xian S X, Yang Z Q, Lee J, et al. A randomized, double-blind, multicenter, placebo-controlled clinical study on the efficacy and safety of Shenmai injection in patients with chronic heart failure [J]. Journal of Ethnopharmacology, 2016, 186(20): 136-142.
/
| 〈 |
|
〉 |
